Pazopanib in ovarian cancer

References

• Cancer Research UK. Cancer incidence and mortality in the UK for the 10 most common cancers. [Internet]. 2014. Available from: http://publications.cancerresearchuk.org/cancerstats/statsincidence/reporttop10incmort.html
   Google Scholar
• GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Internet]. 2012. Available from: http://globocan.iacr.fr/Pages/fact_sheets_population.aspx
   Google Scholar
• National Cancer Institute. SEER stat fact sheets: Cancer of the ovary. [Internet]. 2014. Available from: http://seer.cancer.gov/statfacts/html/ovary.html
   Google Scholar
• Cancer Research UK. Ovarian cancer survival statistics [Internet]. 2014. Available from: www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/survival/ovarian-cancer-survival-statistics
   Google Scholar
• Burger R, Brady MF, Bookman M, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. ICON 7 - A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374(9698):1331-8
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Kumaran G, Jayson G, Clamp A. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100(1):1-7
   PubMed Web of Science ®Google Scholar
• Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6(4):373-8
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank S V, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039-45
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32(13):1302-8
   PubMed Web of Science ®Google Scholar
• Coleman R, Bradya M, Herzog T, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian. In: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, 2015
   Google Scholar
• Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014;32(13):1309-16
   PubMed Web of Science ®Google Scholar
• Ledermann J, Perren T, Raja F, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. Eur J Cancer 2013;49:S5-6
   Web of Science ®Google Scholar
• Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: a randomised placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013;23
   Web of Science ®Google Scholar
• Du Bois A, Floquet A, Kim J-W, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014;32(30):3374-82
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Votrient full prescribing information
   Google Scholar
• Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 2010;15(6):539-47
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006;103(51):19478-83
   PubMed Web of Science ®Google Scholar
• Merritt WM, Nick AM, Carroll AR, et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 2010;9(4):985-95
   PubMed Web of Science ®Google Scholar
• Pazopanib and weekly topotecan in patients recurrent ovarian cancer (TOPAZ). Available from: https://clinicaltrials.gov/ct2/show/NCT01600573
   Google Scholar
• Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15(12):4220-7
   PubMed Web of Science ®Google Scholar
• Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010;88(6):818-23
   PubMed Web of Science ®Google Scholar
• Heath EI, Forman K, Malburg L, et al. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs 2012;30(4):1566-74
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Du Bois A, Vergote I, Wimberger P, et al. Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group. Br J Cancer 2012;106(4):629-32
   PubMed Web of Science ®Google Scholar
• Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15(12):1253-61
   PubMed Web of Science ®Google Scholar
• Burris H, Dowlati A, Moss R, et al. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther 2012;11:1820-8
   PubMed Web of Science ®Google Scholar
• Hainsworth J, Firdaus I, Earwood C, Chua C. Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute. Cancer invest 2015;33(3):47-52
   PubMed Web of Science ®Google Scholar
• Kendra K, Plummer R, Salgia R, et al. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther 2015;14(2):461-9
   PubMed Web of Science ®Google Scholar
• Plummer R, Madi A, Jeffels M, et al. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;71(1):93-101
   PubMed Web of Science ®Google Scholar
• Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol 2015;16(5):561-8
   PubMed Web of Science ®Google Scholar
• Eichbaum M, Schmidt M, Grischke E-M, et al. The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer. J Clin Oncol 2015;33:Suppl; abstr 5557
   Google Scholar
• PAZOFOS: Phase Ib and Phase II trial of pazopanib +/- fosbretabulin in advanced recurrent ovarian cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02055690
   Google Scholar
• Monk B. Bevacizumab with or without fosbretabulin tromethamine in treating patients with recurrent or persistent ovarian epithelial, fallopian tube or peritoneal cavity cancer. In: Society of gynecologic oncology annual meeting on women’s cancer, 2015
   Google Scholar
• Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
   PubMed Web of Science ®Google Scholar
• Richardson D, Sill M, Cho J, et al. A randomised placebo controlled phase IIb trial of weekly paclitaxel plus/minus pazopanib in persistent or recurrent ovarian cancer. In: 15th Biennial meeting of the international gynecologic cancer society, 2014
   Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Hypertension induced by pazopanib. Available from: https://clinicaltrials.gov/ct2/show/NCT01392352
   Google Scholar
• Shibata S, Chung V, Synold T, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute organ dysfunction working group study. Clin Cancer Res 2013;19(13):3631-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722-31
   PubMed Web of Science ®Google Scholar
• Van der Graaf WT, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86
   PubMed Web of Science ®Google Scholar
• Paclitaxel/pazopanib for platinum resistant/refractory ovarian cancer (TAPAZ). Available from: https://clinicaltrials.gov/ct2/show/NCT02383251
   Google Scholar
• Kerklaan B, Lolkema M, Devriese L, et al. Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumours. J Clin Oncol 2013;31:Suppl: 2356
   Google Scholar
• Pazopanib hydrochloride, paclitaxel, and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01402271
   Google Scholar
• A randomized study of safety and efficacy of pazopanib and gemcitabine in persistent or relapsed ovarian cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01610206
   Google Scholar
• [18F]Fluciclatide-PET, Pazopanib and paclitaxel in ovarian cancer (PAZPET-1). Available from: https://clinicaltrials.gov/ct2/show/NCT01608009
   Google Scholar